AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2871058 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 7
Study 31731885 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12
Study 31731885 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 12
Study 30507229 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based evaluative conditioning intervention consisting of six online training sessions of 5 minutes each, where participants clicked on pictures of their own and other people's bodies, with their own pictures followed by portraits of friendly smiling faces.
Number of subjects: 51
Study 30507229 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control condition where participants were shown the same stimuli, but their own body was not paired with smiling faces.
Number of subjects: 51
Study 30507229 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based evaluative conditioning intervention
Number of subjects: 51
Study 30507229 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control condition
Number of subjects: 51
Study 27000036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (eight weekly sessions)
Number of subjects: 45
Study 27000036 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy (eight weekly sessions)
Number of subjects: 45
Study 27000036 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 45
Study 27000036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 45
Study 24119199 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg/day)
Number of subjects: 100
Study 24119199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21917048 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied behaviour analysis (ABA)
Number of subjects: 0
Study 21917048 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 19419253 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 19419253 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor and diuretic combination
Number of subjects: 0
Study 17713154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 30
Study 17713154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) combined with emtricitabine (ADV/FTC)
Number of subjects: 30
Study 17713154 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 15141745 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin from local manufacturer 1
Number of subjects: 12
Study 15141745 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin from local manufacturer 2
Number of subjects: 12
Study 15141745 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin from local manufacturer 3
Number of subjects: 12
Study 15141745 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin from international manufacturer
Number of subjects: 12
Study 12521783 — intervention group
Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 400
Study 12521783 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 400
Study 10198499 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating everything one liked and drinking more (intervention group)
Number of subjects: 71
Study 10198499 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 24 hours with specified limitations (control group)
Number of subjects: 71
Study 7870011 — intervention group
Group type: EXPERIMENTAL
Intervention: HuEPO treatment for anemia in preterm infants
Number of subjects: 0
Study 3276112 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 3276112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 6992229 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 100
Study 6992229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6992229 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting progesterone
Number of subjects: 100
Study 6992229 — intervention group
Group type: EXPERIMENTAL
Intervention: Antispasmodic
Number of subjects: 100
Study 28856932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed training (working memory training)
Number of subjects: 0
Study 28856932 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (low-intensity comparison version of the training)
Number of subjects: 0
Study 30392080 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT adjunct to SRP
Number of subjects: 20
Study 30392080 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20
Study 28526551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay block xenograft (sandwich osteotomy) fixed with mini‐plates
Number of subjects: 16
Study 28526551 — intervention group
Group type: COMPARATOR
Intervention: Onlay particulate xenograft with titanium mesh
Number of subjects: 16
Study 25415767 — intervention group
Group type: EXPERIMENTAL
Intervention: Active product (high-molecular-weight hyaluronan)
Number of subjects: 78
Study 25415767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22797530 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil AP‐X (hybrid composite)
Number of subjects: 46
Study 22797530 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z350 (nanocomposite)
Number of subjects: 46
Study 21896619 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice
Number of subjects: 17
Study 21896619 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 17
Study 21896619 — intervention group
Group type: COMPARATOR
Intervention: Ordinary treatment (Control)
Number of subjects: 17
Study 19500606 — intervention group
Group type: EXPERIMENTAL
Intervention: Amusic group (n=32)
Number of subjects: 53
Study 19500606 — intervention group
Group type: COMPARATOR
Intervention: Non-amusic group (n=21)
Number of subjects: 53
Study 17560080 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss group (dietary weight-loss program: high-fruit/vegetable and low-fat dairy diet or low-fat diet)
Number of subjects: 55
Study 17560080 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss group
Number of subjects: 55
Study 17560080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fruit/vegetable and low-fat dairy diet group (n = 14)
Number of subjects: 55
Study 17560080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 15369941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinch technique before and during DMPA injection
Number of subjects: 78
Study 15369941 — intervention group
Group type: COMPARATOR
Intervention: Injection only (control group)
Number of subjects: 78
Study 11600531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 0.3 mg daily
Number of subjects: 770
Study 11600531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 0.625 mg daily
Number of subjects: 770
Study 11600531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg daily
Number of subjects: 770
Study 11600531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 770
Study 11600531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study 9682807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study 9682807 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 10
Study 9682807 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 10
Study 7914564 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 1301
Study 7914564 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 1301
Study 2459988 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (dosage not specified)
Number of subjects: 0
Study 241119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin stearate (500 mg twice or 3 times a day for 10 days)
Number of subjects: 76
Study 31284175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (DEX)
Number of subjects: 0
Study 31284175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28597081 — intervention group
Group type: COMPARATOR
Intervention: Bright light (BRIGHT)
Number of subjects: 72
Study 28597081 — intervention group
Group type: COMPARATOR
Intervention: Monochromatic blue light (BLUE)
Number of subjects: 72
Study 28597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Control condition (CONTROL)
Number of subjects: 72
Study 26144593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low (2.9%)-THC vaporized cannabis
Number of subjects: 18
Study 26144593 — intervention group
Group type: EXPERIMENTAL
Intervention: High (6.7%)-THC vaporized cannabis
Number of subjects: 18
Study 26144593 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.05g/210L and 0.08g/210L)
Number of subjects: 18
Study 26144593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-alcohol combination (5μg/L THC + 0.05g/210L alcohol)
Number of subjects: 18
Study 26144593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23460688 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused intervention (six 2-hour dietitian-delivered sessions over 15 months)
Number of subjects: 542
Study 23460688 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 newsletters on nonobesity-focused themes)
Number of subjects: 542
Study 21401541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular compression using an external pressure device for 20 min before combined peri- and retrobulbar injection
Number of subjects: 60
Study 21401541 — intervention group
Group type: COMPARATOR
Intervention: Control group with pressure applied only after the block was completed
Number of subjects: 60
Study 19336453 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice a day) plus optimized background therapy (OBT)
Number of subjects: 51
Study 17353499 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber DASH diet (30 g/d)
Number of subjects: 35
Study 17353499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-supplemented diet (30 g/d)
Number of subjects: 35
Study 15115860 — intervention group
Group type: COMPARATOR
Intervention: Eotaxin 20 microg
Number of subjects: 16
Study 15115860 — intervention group
Group type: COMPARATOR
Intervention: Eotaxin 40 microg
Number of subjects: 16
Study 15115860 — intervention group
Group type: EXPERIMENTAL
Intervention: Eotaxin 5, 10, and 20 microg
Number of subjects: 16
Study 11482684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine and cimetidine
Number of subjects: 0
Study 11482684 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine and placebo
Number of subjects: 0
Study 9505883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneously)
Number of subjects: 12
Study 8172146 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. (group I; n = 35)
Number of subjects: 70
Study 8172146 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.i.d. plus amoxicillin 1 g b.i.d. (group II; n = 35)
Number of subjects: 70
Study 8172146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 3370890 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight catheterization in the recovery room
Number of subjects: 54
Study 3370890 — intervention group
Group type: COMPARATOR
Intervention: Not straight catheterized (control group)
Number of subjects: 54
Study 31661579 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with 12 weeks of education (I-group)
Number of subjects: 98
Study 31661579 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (C-group)
Number of subjects: 98
Study 31661579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I-group and C-group)
Number of subjects: 98
Study 29622380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 150 mg
Number of subjects: 30
Study 29622380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 30
Study 29622380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 600 mg
Number of subjects: 30
Study 29622380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab (150, 300, or 600 mg)
Number of subjects: 30
Study 29622380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg)
Number of subjects: 30
Study 28258661 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CEM LinkAceTM
Number of subjects: 3
Study 28258661 — intervention group
Group type: EXPERIMENTAL
Intervention: BisCem®
Number of subjects: 3
Study 28258661 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem EliteTM
Number of subjects: 3
Study 28258661 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia
Number of subjects: 3
Study 28258661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate
Number of subjects: 3
Study 28258661 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia and lithium disilicate
Number of subjects: 3
Study 25328082 — intervention group
Group type: EXPERIMENTAL
Intervention: G. kola 12.5 g once daily for 7 days (group A)
Number of subjects: 24
Study 25328082 — intervention group
Group type: EXPERIMENTAL
Intervention: G. kola 12.5 g twice daily for 6 days and once on the seventh day (group B)
Number of subjects: 24
Study 25328082 — intervention group
Group type: COMPARATOR
Intervention: Quinine with G. kola
Number of subjects: 24
Study 24211339 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 0
Study 24211339 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse Attention Bias Modification (inverse ABM)
Number of subjects: 0
Study 24211339 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 21553071 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 76
Study 21553071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblaster
Number of subjects: 76
Study 21553071 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser/sandblaster
Number of subjects: 76
Study 21553071 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Control Group 1)
Number of subjects: 76
Study 18440385 — intervention group
Group type: EXPERIMENTAL
Intervention: UT‐EGD method
Number of subjects: 28
Study 18440385 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 28
Study 18440385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 28
Study 17968657 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Matters prevention curriculum
Number of subjects: 28
Study 17968657 — intervention group
Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 28
Study 12950483 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage-based e-mail system
Number of subjects: 2
Study 12950483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to e-mail system)
Number of subjects: 2
Study 11009233 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% intrathecal ropivacaine (ROP)
Number of subjects: 12
Study 11009233 — intervention group
Group type: COMPARATOR
Intervention: 0.5% intrathecal bupivacaine (BUP)
Number of subjects: 12
Study 8695028 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 37
Study 8695028 — intervention group
Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 37
Study 1587589 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-1 vaccine (1.0 x 10(9) CFU)
Number of subjects: 13
Study 1587589 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (1.5 x 10(11) CFU in three doses)
Number of subjects: 13
Study 1587589 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (2.5 x 10(9) CFU)
Number of subjects: 13
Study 1587589 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (1.8 x 10(10) CFU)
Number of subjects: 13
Study 1587589 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (1.2 to 2.5 x 10(9) CFU in three doses)
Number of subjects: 13
Study 1587589 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine
Number of subjects: 13
Study 1587589 — intervention group
Group type: COMPARATOR
Intervention: E. coli K-12 placebo
Number of subjects: 13
Study 4029558 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (94%)
Number of subjects: 11
Study 4029558 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymers
Number of subjects: 11
Study 29119275 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 17
Study 29119275 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study 26393389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1061
Study 26393389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 26393389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061
Study 24849793 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Sports Resort training plus usual therapy
Number of subjects: 62
Study 24849793 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 62
Study 22138200 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral intervention delivered by telephone
Number of subjects: 196
Study 22138200 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 196
Study 20383504 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole prophylaxis
Number of subjects: 0
Study 20383504 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 0
Study 19192438 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 1 mg
Number of subjects: 76
Study 19192438 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 3 mg
Number of subjects: 76
Study 19192438 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 76
Study 19192438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15758622 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 3 mg enema once daily for 6 weeks
Number of subjects: 217
Study 15758622 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA (mesalamine) 1 g enema daily for 6 weeks
Number of subjects: 217
Study 12091296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 30
Study 12091296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10323605 — intervention group
Group type: EXPERIMENTAL
Intervention: HGH (0.1 mg/kg/day)
Number of subjects: 60
Study 10323605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (20 mg/day)
Number of subjects: 60
Study 10323605 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 10323605 — intervention group
Group type: EXPERIMENTAL
Intervention: HGH
Number of subjects: 60
Study 10323605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 60
Study 10323605 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 8759894 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) (8 mg/m2, i.v., days 1-5)
Number of subjects: 251
Study 8759894 — intervention group
Group type: COMPARATOR
Intervention: Zorubicin (ZRB) (200 mg/m2, i.v., days 1-4)
Number of subjects: 251
Study 8759894 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy with high-dose Ara-C (3 g/m2, 3 h infusion, q 12 h, days 1-4) and m-Amsa (100 mg/m2/d, i.v., days 5-7)
Number of subjects: 251
Study 8759894 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 251
Study 1929586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 0
Study 1929586 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 1929586 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 0
Study 6352185 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.0 mg/day for 4 weeks
Number of subjects: 10
Study 6352185 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day for 4 weeks
Number of subjects: 10
Study 6352185 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 5.0 mg/day for 4 weeks
Number of subjects: 10
Study 6352185 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (all doses)
Number of subjects: 10
Study 31498145 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based hand resistance exercise (30 min/day, 5 days/week, for 6 weeks with 70% of the 1-repetition maximum)
Number of subjects: 50
Study 31498145 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual exercise by occupational therapist (same duration and frequency as experimental group)
Number of subjects: 50
Study 31498145 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based hand resistance exercise
Number of subjects: 50
Study 31498145 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual exercise
Number of subjects: 50
Study 29174926 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 85
Study 29174926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 26909960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii pills (orally administered) for three courses of treatment, each consisting of 4 weeks, in addition to conventional western medicine.
Number of subjects: 82
Study 26909960 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine (control group).
Number of subjects: 82
Study 26909960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (observation and control).
Number of subjects: 82
Study 26909960 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (T. wilfordii + conventional medicine).
Number of subjects: 82